These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 37725919)

  • 21. The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia.
    Pitt B; Garza D
    Expert Opin Drug Saf; 2018 May; 17(5):525-535. PubMed ID: 29667438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease.
    Evans M; Palaka E; Furuland H; Bennett H; Linde C; Qin L; McEwan P; Bakhai A
    BMC Nephrol; 2019 Jan; 20(1):31. PubMed ID: 30704421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K
    Murphy D; Ster IC; Kaski JC; Anderson L; Banerjee D
    BMC Nephrol; 2021 Jul; 22(1):254. PubMed ID: 34229607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness Analysis of Patiromer in Combination with Renin-Angiotensin-Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden.
    Widén J; Ivarsson M; Schalin L; Vrouchou P; Schwenkglenks M; Heimbürger O; Ademi Z; Sutherland CS
    Pharmacoeconomics; 2020 Jul; 38(7):747-764. PubMed ID: 32239480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
    Jun M; Jardine MJ; Perkovic V; Pilard Q; Billot L; Rodgers A; Rogers K; Gallagher M
    PLoS One; 2019; 14(3):e0213192. PubMed ID: 30845156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness of Treating Patients with Chronic Kidney Disease and Prior Hyperkalemia with Renin-Angiotensin-Aldosterone System Inhibitor and Patiromer: A Swiss Public Healthcare Perspective.
    Fischer B; Serra A; Telser H
    Adv Ther; 2022 Jun; 39(6):2717-2730. PubMed ID: 35416597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia.
    Kanda E; Rastogi A; Murohara T; Lesén E; Agiro A; Arnold M; Chen G; Yajima T; Järbrink K; Pollack CV
    BMC Nephrol; 2023 Jan; 24(1):18. PubMed ID: 36658531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life.
    Esteban-Fernández A; Ortiz Cortés C; López-Fernández S; Recio Mayoral A; Camacho Jurado FJ; Gómez Otero I; Molina M; Almenar Bonet L; López-Vilella R
    ESC Heart Fail; 2022 Oct; 9(5):3071-3078. PubMed ID: 35748119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
    Pitt B; Bushinsky DA; Kitzman DW; Ruschitzka F; Metra M; Filippatos G; Rossignol P; Du Mond C; Garza D; Berman L; Lainscak M;
    ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discontinuation of RAAS Inhibition in Children with Advanced CKD.
    van den Belt SM; Heerspink HJL; Kirchner M; Gracchi V; Thurn-Valsassina D; Bayazit AK; Niemirska A; Canpolat N; Kaplan Bulut I; Azukaitis K; Duzova A; Bacchetta J; Shroff R; Paripovic D; Özçakar ZB; Fidan K; Erdogan H; Gellermann J; Wühl E; de Zeeuw D; Melk A; Querfeld U; Schaefer F
    Clin J Am Soc Nephrol; 2020 May; 15(5):625-632. PubMed ID: 32253275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world management of hyperkalemia with patiromer among United States Veterans.
    Kovesdy CP; Gosmanova EO; Woods SD; Fogli JJ; Rowan CG; Hansen JL; Sauer BC
    Postgrad Med; 2020 Mar; 132(2):176-183. PubMed ID: 31971043
    [No Abstract]   [Full Text] [Related]  

  • 32. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.
    Butler J; Anker SD; Lund LH; Coats AJS; Filippatos G; Siddiqi TJ; Friede T; Fabien V; Kosiborod M; Metra M; Piña IL; Pinto F; Rossignol P; van der Meer P; Bahit C; Belohlavek J; Böhm M; Brugts JJ; Cleland JGF; Ezekowitz J; Bayes-Genis A; Gotsman I; Goudev A; Khintibidze I; Lindenfeld J; Mentz RJ; Merkely B; Montes EC; Mullens W; Nicolau JC; Parkhomenko A; Ponikowski P; Seferovic PM; Senni M; Shlyakhto E; Cohen-Solal A; Szecsödy P; Jensen K; Dorigotti F; Weir MR; Pitt B
    Eur Heart J; 2022 Nov; 43(41):4362-4373. PubMed ID: 35900838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study.
    Agiro A; An A; Cook EE; Mu F; Chen J; Desai P; Oluwatosin Y; Pollack CV
    Adv Ther; 2023 Jun; 40(6):2886-2901. PubMed ID: 37140706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics.
    Weir MR; Mayo MR; Garza D; Arthur SA; Berman L; Bushinsky D; Wilson DJ; Epstein M
    J Hypertens; 2017 May; 35 Suppl 1(Suppl 1):S57-S63. PubMed ID: 28129247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Sodium Zirconium Cyclosilicate Plus Renin-Angiotensin-Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study.
    Dwyer JP; Agiro A; Desai P; Oluwatosin Y
    Adv Ther; 2023 Nov; 40(11):4777-4791. PubMed ID: 37606716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperkalaemia-related reduction of RAASi treatment associates with more subsequent inpatient care.
    Svensson MK; Murohara T; Lesén E; Arnold M; Cars T; Järbrink K; Chen G; Morita N; Venkatesan S; Kanda E
    Nephrol Dial Transplant; 2024 Jul; 39(8):1258-1267. PubMed ID: 38253386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease].
    Degli Esposti L; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Santoro A
    G Ital Nefrol; 2019 Sep; 36(5):. PubMed ID: 31580544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
    Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
    J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic impact of the use of patiromer in chronic kidney disease or heart failure for the treatment of chronic hyperkalemia in Spain.
    de Sequera P; Bover R; Ivanova-Markova Y; Ivanova A; González-Domínguez A; Valls M; Campos V
    Nefrologia (Engl Ed); 2023; 43(6):721-730. PubMed ID: 38228463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.